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Abstract
Context: Connective tissue cells include fibroblasts, chondrocytes, adipocyte, and osteocytes. These cells are specialized for the secretion 
of collagenous extracellular matrix and are responsible for the architectural framework of the human body.
Evidence Acquisition: Connective tissue cells play a central role in supporting as well as repairing tissues and organs. Fibroblast cell 
therapy could be used for the treatment of burn wounds, scars, diabetic foot ulcers, acne scars and skin aging. This review focused on 
biology of fibroblasts and their role in cell therapy of recessive dystrophic epidermolysis bullosa (RDEB).
Results: Fibroblasts are known to play a pivotal role in skin structure and integrity, and dermal fibroblasts are believed to promote skin 
regeneration and rejuvenation via collagen production.
Conclusions: Fibroblasts can be used in transplantations to ameliorate an immune system response, in order to reduce antigen 
production. Human fibroblasts suppress ongoing mixed lymphocyte reactions (MLRs) between lymphocyte cells from two individuals, 
and supernatant materials from fibroblast cultures suppress MLRs.
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1. Context
1.1. Cell Therapy
Cell therapy, first introduced in the nineteenth century, 
is defined as the transplantation of cellular material into a 
patient. Various cell therapies are emerging worldwide as 
new treatment modalities in clinical medicine. In this pro-
cess, autologous or allogeneic cells and materials are prop-
agated, expanded, selected, pharmacologically treated, or 
otherwise altered in biological materials to prevent, treat, 
or diagnose disease. For example, standard approaches to 
improve wound healing may speed re-epithelialization, 
but skin function will remain compromised; a novel ap-
proach to promote skin regeneration is the introduction 
of fibroblasts into the wound (Figure 1) (1).
Figure 1. Application of Cultured Allogeneic Fibroblasts in Wound Repair
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1.2. Recessive Dystrophic Epidermolysis Bullosa 
(RDBE)
RDBE is a group of autosomal-dominant blistering skin 
diseases caused by mutations in the collagen VII gene 
(COL7A1) and subsequent abnormalities in the anchor-
ing fibrils (collagen type VII) (2). Collagen VII is the major 
constituent of the basement membrane, and defects in it 
are characterized by dermal-epidermal separation below 
the lamina densa (3). It has been demonstrated that CO-
L7A1 is not only vital for maintaining skin integrity, but is 
also a critical player in skin-wound healing (4).
The DDEB phenotype is characterized by recurrent blister-
ing; milia; atrophic scarring; erosions; crusts; nail dystro-
phy with eventual loss of nails; functionally disabling con-
tractures in the hands, feet, elbows, and knees; and a high 
risk of developing aggressive squamous cell carcinoma (5).
Skin consists of two layers, the epidermis and the der-
mis, the main cells of which are keratinocytes and fibro-
blasts, respectively. In vivo, both fibroblasts and kerati-
nocytes produce collagen VII (6); however, keratinocytes 
are the major cell source for its synthesis in the basement 
membrane zone (7). It is easier to culture fibroblasts than 
keratinocytes, and therefore fibroblasts may be a supe-
rior cell-source target for skin-cell therapy (8).
2. Evidence Acquisition
2.1. Fibroblast Features
Fibroblasts, the most common cells in connective tissues, 
are resident mesenchymal cells that produce extracellular 
matrix (ECM) proteins. Fibroblasts are major cellular con-
stituents of the skin dermal layer, expressing the interme-
diate filament protein known as vimentin, which is used 
as a marker to test their mesodermal origin. However, this 
test is not specific, as epithelial cells cultured in vitro on 
adherent substratum may also express vimentin (9).
2.1.1. Types of Fibroblasts
Fibroblasts in different tissues have different morphol-
ogies and gene-expression profiles. ECM proteins and cy-
tokines are synthesized by fibroblasts in a tissue-specific 
manner (10, 11). Dermal fibroblasts have numerous func-
tions, not only in synthesizing ECM proteins, but also in 
proliferation and migration in response to chemotactic, 
mitogenic, and modulatory cytokines, and in autocrine 
and paracrine interactions (12). Dermal fibroblasts have 
been evaluated for other applications, such as ligament 
regeneration (13).
2.1.2. Fibroblast Secretion Materials
In the dermis, fibroblasts produce different types of 
collagens (I, III, and VII), elastic fibers (elastic, oxytalan), 
matrix metalloproteinases (MMPs), glycosaminoglycans, 
glycoproteins, and cytokine human thymic stromal lym-
phopoietin (TSLP) (Box 1) (14).
Box 1. Materials Secreted by Fibroblasts
Materials
Collagens (type I, III, and VII)
Elastin
Hyaluronic acid (hyaluronan)
Matrix metalloproteinases 
Glycosaminoglycans
Reticular and elastic fibers
Cytokine human thymic stromal lymphopoietin
3. Results
3.1. Wound Healing and Fibroblasts
Fibroblasts are known to play a pivotal role in skin struc-
ture and integrity, and dermal fibroblasts are believed to 
promote skin regeneration and rejuvenation via collagen 
production (15).
Wound healing is a complex process that involves four 
phases: hemostasis, inflammation, granulation (prolif-
eration), and maturation (remodeling). In hemostasis, 
platelets seal off the damaged blood vessels within min-
utes of the initial injury to reduce blood loss, and fill the 
tissue gap with a blood clot. In the inflammation stage, 
plasma infiltrates through the blood vessels, and neutro-
phils immigrate into the surrounding tissue, where they 
phagocytose the debris and microorganisms for four days 
post-injury. During the inflammation phase, circulating 
monocytes exit the blood vessels, differentiate into macro-
phages, and come into contact with the ECM. Macrophages 
also phagocytose bacteria and provide a second line of 
defense. Under the influence of inflammatory cytokines, 
macrophages secrete extracellular enzymes to degrade 
the necrotic tissue. These enzymes, called matrix metal-
loproteases (MMPs), are responsible for removing the ne-
crotic tissue and repairing the remaining damaged tissue.
Approximately four days after the injury, the prolifera-
tion phase occurs. This is characterized by angiogenesis, 
fibroblast proliferation and differentiation, collagen de-
position, granulation tissue formation, wound contrac-
tion, and epithelialization. During this phase, fibroblasts 
secrete the collagen framework, on which further dermal 
regeneration occurs. During the proliferation process, 
ECM proteins act as scaffolds for migrating inflammatory 
cells and the generation of granulation tissue, which pro-
vides the temporary substrate upon which re-epithelial-
ization by keratinocyte cells takes place (16). Fibroblasts 
also have the capacity to differentiate into myofibroblasts, 
which generate wound contracture. The keratinocytes are 
responsible for re-epithelialization in the final stage of epi-
thelialization (17). In response to the wound, macrophages 
and fibroblasts also release growth factors that lead to fur-
ther fibroblast migration and proliferation (18).
In the remodeling phase of wound healing, myofibro-
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blasts undergo apoptosis, resulting in decreased cell 
density, while the remaining dermal fibroblasts begin to 
produce type I collagen in order to create greater tensile 
strength. This plasticity of fibroblasts as they transition 
from producing ECM to promoting wound contracture, 
and their synthesis of type 1 collagen, makes them a favor-
able candidate for cellular therapy in wound healing (11).
3.1.1. Application of Fibroblasts in Skin Cell Therapy
Dermal fibroblasts are used in the treatment of surgical 
and burn wounds, chronic wounds such as diabetic and 
pressure ulcers, and acne scars, as well as for cosmetic pur-
poses, such as treating facial rhytides and skin-aging (17).
3.2. Allogeneic Fibroblasts
The fibroblasts used in skin cell therapies may be alloge-
neic or autologous. Autologous fibroblasts carry no risk 
of rejection or cross-infection, but autologous fibroblasts 
require 3 - 4 weeks of cultivation to obtain sufficient cell 
numbers; therefore, allogeneic fibroblasts are a superior 
source for cell therapies (19), and they are often obtained 
from foreskin samples. After isolation, these cells are cul-
tured, then cryopreserved at −196°C (20).
3.2.1. Immunogenicity of Allogeneic Fibroblasts
The viability of allogeneic fibroblasts implanted into a 
wound remains controversial because of possible immune 
rejection. However, there have been 88000 fibroblast cul-
tures implanted into wounds, corresponding to more than 
20000 patients, without any observed acute immune rejec-
tions. The absence of antibody formation against allogene-
ic fibroblasts is seen in 50% of patients, and the absence of 
T-cell activation is reported in 25% of patients (13).
It has been reported that after allogeneic fibroblast 
transplantation, these cells should be able to integrate 
with the host tissues (20). Allogeneic living fibroblasts 
are known to have been successfully applied in different 
types of wounds (21).
Autologous dermal fibroblast transplantation holds 
enormous promise in the field of regenerative medicine, 
offering a simple alternative for tissue-regeneration ap-
plications. Basic research into the mechanism(s) of re-
gional phenotype determination by fibroblasts will help 
in the development of reprogramming options for cell 
therapy applications (22).
3.3. Therapeutic Indications
In a double-blinded, randomized, placebo-controlled 
trial that assessed allogeneic fibroblasts in RDEB, 20 pa-
tients were screened; seven were excluded and five were 
selected. Six pairs of symmetrical lesions in each patient 
were selected, and one side received a single intrader-
mal injection of cultured allogeneic fibroblasts while 
the other side received vehicle solution (Transalyte with 
2% Albumex). After 12 months of follow-up, skin biopsy 
was performed, and blood tests, quality of life question-
naires, and wound dimensions were assessed. No benefit 
was detected with allogeneic fibroblasts, as similar im-
provement was described in both groups.
In an open-label study, injecting cultured allogeneic fi-
broblasts into RDEB wounds led to clinical improvement 
in some patients. A recently completed Phase II clinical 
trial of fibroblast cellular therapy for RDEB built on a 
great deal of laboratory research and the previous pilot 
trial, in which 15 patients with RDEB showed that injec-
tions of fibroblasts from unrelated donors into the skin 
were apparently safe and had the potential to improve 
skin strength and to reduce blistering. The majority of 
the wound healing benefits developed during the first 28 
days of a single injection (23) (Figures 2 and 3).
Figure 2. Fifteen Patients With Dystrophic EB Received a Single Series of 
Intradermal Injections of Cultured Allogeneic Fibroblasts (Vavelta, Inter-
cytex, UK)
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Figure 3. Patients with Dystrophic EB Received a Single Series of Intradermal Injections of Cultured Allogeneic Fibroblasts (Vavelta, Intercytex, UK) and 
Vehicle on Day 0 and Day 28
Table 1. Cellular Substitutes Using Allogeneic Fibroblasts
Manufacturer Brand Name Material
Organogenesis, Canton, MA Apligraf™ (earlier name: Graftskin™) Collagen gel + cult. Allog. HuK + allog. HuFi
Genzyme Biosurgery, Cambridge, MA Epicell™ Cult. Autol HuK
Advanced Tissue, La Jolla, CA Transcyte™ PGA/PLA + ECMP DAHF
Integra LifeScience, Plainsborough, NJ Integra™ Collagen GAG-silicone foil
Lifecell Corporation, Branchberg, NJ AlloDerm™ Acellular dermis
Fidia Advanced Biopolymers, Padua, Italy Laserskin™ HAM + cult. HuK
Advanced Tissue Sciences, La Jolla, CA Dermagraft™ PGA/PLA + allog. HuFi
Ortec International, Inc., New York, NY Orcel™ Collagen + allog HuFi + allog HuK
BioTissue Technologies, Freiburg, Germany Bioseed™ Fibrin sealant + cult. autol HuK
HC Implants Polyactive™ PEO/PBT + autol. HuFi + cult autol HuK
Fidia Advanced Biopolymers, Padua, Italy Hyalograft 3D™ HAM + HuFi
Dow Hickham/Bertek Pharmac., Sugarland, TX Biobrane™ Silicone + nylon mesh + collagen
3.4. Bio-Engineered Skin
Artificial skins and soft-tissue substitutes may be either 
acellular or cellular. Acellular products contain a matrix 
composed of materials such as collagen and fibronectin 
(24). Cellular products contain living cells, including fi-
broblasts and keratinocytes, within a matrix. Such prod-
ucts are widely used in clinics and include Dermagraft, 
Hyalograft, Orcel, Apligraf, ICX-SKN, and VCT01 (Box 1 and 
Table 1) (Figure 4) (25).
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Figure 4. Appearance of Apligraf
A, Apligraf being removed from its pink nutrient agar; B, held just prior to fenestration or meshing; C, after fenestration with a scalpel; D, after meshing 
at a 1.5:1 ratio. Copyright V. Falanga, 2006.
4. Conclusions
Fibroblasts can be used in transplantations to amelio-
rate an immune system response, in order to reduce an-
tigen production. Human fibroblasts suppress ongoing 
mixed lymphocyte reactions (MLRs) between lympho-
cyte cells from two individuals, and supernatant materi-
als from fibroblast cultures suppress MLRs. Supernatants 
from fibroblast cultures of different individuals do not 
exhibit specificity of the reduced response with regard 
to major histocompatibility complex type. The collected 
data indicate that allogeneic fibroblasts are capable of 
surviving at a wound site for at least six months, and we 
did not have any findings of acute immunologic rejec-
tion of allogeneic fibroblasts. Further studies are needed 
to evaluate the mechanism of action of dermal fibro-
blasts in promoting the formation of new type VII colla-
gen in wounds.
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